Tuesday, December 13, 2016 12:30:55 PM
A Promising New Alzheimer’s Treatment Drug
The Problem. Alzheimer’s disease debilitates and kills ever-increasing numbers of aging Americans. The Alzheimer’s Foundation of America estimates that as many as 5.1 million Americans may have the disease, and the number is increasing with our large, aging population. The disease is devastating to both its victims and their care givers. Treatments and care-giving costs are massive, stretching collectively into the many billions of dollars.
Treatments. Effectively, there are none presently. A few, very expensive drugs can temporarily, for just a few weeks or months, merely slow the aggravating progression of symptoms. No treatment drug or protocol either stops or cures the inevitable progression to profound disability and ultimate death from the disease. A diagnosis of Alzheimer’s disease is a curse for which modern medicine offers no hope.
Treatment Research. The cause of Alzheimer’s symptoms is almost universally perceived to be the accumulation in or near nerve cells (neurons) of two waste proteins, agglomerations of beta-amyloid plaque, and neurofibrillary tangles, insoluble twisted fibers composed largely of the protein tau, composing the tau tangles.
Current research has strived to remove these neuron wastes that complicate normal brain nerve functions. Plainly, and tragically, all of these efforts have failed. The research drugs targeted at waste proteins have either failed to reduce their presence, or have concomitantly caused serious, even lethal side effects.
The other approach has been to prompt the immune system to chemically destroy and remove the waste proteins. These efforts, too, have failed in every case.
Until now, there have been no drugs that have demonstrated any safe, effective potential to successfully treat Alzheimer’s in any useful way. The disease continues to be an un-treatable curse.
Until now.
A Successful New Drug in Development. A different treatment approach is required. Instead to attempting to pharmaceutically remove beta-amyloid plaques and tau tangles, one company’s researchers have intelligently targeted — successfully — the root cause of those waste protein agglomerations. Instead of attempting to remove them after their formation, after they persist and continue to cause nerve dysfunction, the new approach is to keep them from ever forming, or facilitate their removal by natural, innate cellular processes (as occurs in normal, non-diseased neurons). This approach will revolutionize Alzheimer’s treatment (along with a number of other neurodegenerative diseases).
Children and young adults virtually never get Alzheimer’s. It appears in middle to older aged individuals; after earlier years of mental normalcy. With age, neurons in many people fail to work normally. The new drug restores youthful “homeostasis,” consistent, normal cell status or function, in a powerfully unique and successful way.
The proper function of two structures, organelles, in the neuron are essential. Mitochondria are tiny cellular structures that extract energy from digested food molecules and store that energy in adenosine triphosphate, ATP. ATP is then used in virtually all cellular reactions and processes to power them. ATP is the cell’s energy resource. Without adequate ATP, cellular processes are diminished or inhibited, and disease ensues.
The other essential organelle is the endoplasmic reticulum. Endoplasmic reticula (among other things) take ATP from adjacent, connected mitochondria and use its energy to properly fold and lock together complex proteins, primarily essential enzymes. Virtually all cellular chemistry is mediated by controlling enzymes, much as a key unlocks a lock. If a key, in this case an enzyme in a neuron, is bent or misfolded, the lock, or the life-supporting chemical reaction cannot occur.
In most neurodegenerative conditions, especially Alzheimer’s, endoplamic reticula become separated from the mitochondria. They no longer can receive sufficient ATP to properly fold proteins into normal reaction-controlling enzymes. The cell fails to function properly, or even dies (as in the case of advanced Alzheimer’s neurons).
The solution? Find a molecule that re-connects and maintains the mitochondrion-endoplasmic reticulum connection. Keep the two organelles connected, so proper, healthful enzymes can be normally synthesized — as was the case before Alzheimer’s struck.
The Revolutionizing Molecule. Wonderfully, such a molecule has been found, and has been tested in early trials on humans, with extremely positive results. The molecule is Anavex 2-73, a patented proprietary chemical of Anavex Life Sciences Corp. (AVXL:NASDAQ).
Early clinical trials of Anavex 2-73 have established the following facts.
1. Few or No Side Effects. After a year of administration to people with mid to moderate levels of Alzheimer’s, no serious, debilitating, or disqualifying side effects appeared. For drugs treating nerve or brain conditions, this is exceptionally rare.
2. Stops or Improves Alzheimer’s Symptoms. Remarkably, Anavex 2-73 in dosing ranges between 10 to 50 mg (very small amounts) in a one-year clinical trial period, either a) stopped the progression of symptoms, keeping them at the initial dosing level; or b) remarkably reversed the severity of symptoms, trending at the end of the 52-week trial toward mental and functional normalcy.
Larger, substantiating clinical trials of Anavex 2-73 for Alzheimer’s should be forthcoming. But preliminary lab data in animals, followed by the profound findings of the recently-reported clinical trial in humans are revolutionary. Now, there is profound hope for a) successful treatment of Alzheimer’s, and b) termination of the progression of the disease at its earliest, mildest degrees.
The Future. Anavex 2-73 holds the promise of solving the expanding Alzheimer’s problem, first in America, and then in the rest of the world. The sooner Food and Drug Administration (FDA) approval is attained for this safe and effective drug, the sooner millions will no longer be medically and financially ruined by this frightful disease.
*******************
Study Data. Scrutinize the clinical results of an early 52-week trial of Anavex 2-73 here:
http://www.anavex.com/wp-content/uploads/CTAD-Anavex-December-2016-2.pdf
Notice the minimal and insignificant adverse events (side effects) on page 18.
The data plot on page 25 (the yellow doted line) shows cognition results.
Page 33 enumerates the positive results of Anavex 2-73
Recent AVXL News
- Anavex Life Sciences Announces Expansion of Leadership Team • GlobeNewswire Inc. • 05/22/2024 11:30:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/17/2024 10:01:00 AM
- Anavex Life Sciences to Present at the H.C. Wainwright 2nd BioConnect Investor Conference at NASDAQ • GlobeNewswire Inc. • 05/14/2024 11:30:00 AM
- Shareholders that lost money on Anavex Life Sciences Corporation(AVXL) Urged to Join Class Action - Contact The Gross Law Firm to Learn More • PR Newswire (US) • 05/10/2024 09:45:00 AM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/09/2024 08:35:55 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/09/2024 12:00:30 PM
- Anavex Life Sciences Reports Fiscal 2024 Second Quarter Financial Results and Provides Business Update • GlobeNewswire Inc. • 05/09/2024 11:30:00 AM
- The Gross Law Firm Announces the Filing of a Securities Class Action on Behalf of Anavex Life Sciences Corporation(AVXL) Shareholders • PR Newswire (US) • 05/07/2024 09:45:00 AM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 05/06/2024 10:03:33 AM
- Anavex Life Sciences Corporation Sued for Securities Law Violations - Contact The Gross Law Firm Before May 13, 2024 to Discuss Your Rights - AVXL • PR Newswire (US) • 05/03/2024 09:45:00 AM
- Anavex Life Sciences to Announce Fiscal 2024 Second Quarter Financial Results on Thursday, May 9th, 2024 • GlobeNewswire Inc. • 05/02/2024 11:30:00 AM
- May 13, 2024 Deadline: Contact The Gross Law Firm to Join Class Action Suit Against AVXL • PR Newswire (US) • 04/26/2024 09:45:00 AM
- Contact The Gross Law Firm by May 13, 2024 Deadline to Join Class Action Against Anavex Life Sciences Corporation(AVXL) • PR Newswire (US) • 04/19/2024 09:45:00 AM
- The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of May 13, 2024 in Anavex Life Sciences Lawsuit - AVXL • PR Newswire (US) • 04/16/2024 09:45:00 AM
- Class Action Filed Against Anavex Life Sciences Corporation (AVXL) - May 13, 2024 Deadline to Join - Contact The Gross Law Firm • PR Newswire (US) • 04/12/2024 09:45:00 AM
- Anavex Life Sciences to Present at the Noble Capital Markets Virtual Healthcare Equity Conference • GlobeNewswire Inc. • 04/11/2024 11:30:00 AM
- Class Action Filed Against Anavex Life Sciences Corporation (AVXL) - May 13, 2024 Deadline to Join - Contact The Gross Law Firm • PR Newswire (US) • 04/09/2024 09:45:00 AM
- Anavex Life Sciences Corporation Class Action: The Gross Law Firm Reminds Anavex Life Sciences Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of May 13, 2024 - AVXL • PR Newswire (US) • 04/05/2024 09:45:00 AM
- Shareholders that lost money on Anavex Life Sciences Corporation(AVXL) should contact The Gross Law Firm about pending Class Action - AVXL • PR Newswire (US) • 04/02/2024 09:45:00 AM
- Lost Money on Anavex Life Sciences Corporation(AVXL)? Join Class Action Suit Seeking Recovery - Contact The Gross Law Firm • PR Newswire (US) • 03/29/2024 09:45:00 AM
- Investors who lost money on Anavex Life Sciences Corporation(AVXL) should contact The Gross Law Firm about pending Class Action - AVXL • PR Newswire (US) • 03/26/2024 09:45:00 AM
- Anavex Life Sciences to Present at the 23rd Annual Needham Virtual Healthcare Conference • GlobeNewswire Inc. • 03/25/2024 11:30:00 AM
- The Gross Law Firm Notifies Anavex Life Sciences Corporation Investors of a Class Action Lawsuit and Upcoming Deadline • PR Newswire (US) • 03/22/2024 09:45:00 AM
- Anavex Life Sciences Initiates Placebo-Controlled U.S. Phase 2 Clinical Trial of ANAVEX®3-71 in Schizophrenia • GlobeNewswire Inc. • 03/18/2024 11:30:00 AM
ECGI Holdings Announces LOI to Acquire Pacific Saddlery to Capitalize on $12.72 Billion Market Potential • ECGI • Jun 13, 2024 9:50 AM
Fifty 1 Labs, Inc. Announces Major Strategic Advancements and Shareholder Updates • CAFI • Jun 13, 2024 8:45 AM
Snakes & Lattes Opens Pop-Up Location at The Wellington Market in Toronto: A New Destination for Fun and Games - Thanks 'The Well', PepsiCo, Indie Pale House & All Sponsors & Partners for Their Commitment & Assistance Throughout The Process • FUNN • Jun 13, 2024 8:18 AM
HealthLynked Introduces Innovative Online Medical Record Request Form Using DocuSign • HLYK • Jun 12, 2024 8:00 AM
Ubiquitech Software Corp (OTC:UBQU) Posts $624,585 Quarterly Revenue - Largest Quarter Since 2018 • UBQU • Jun 11, 2024 10:13 AM
Element79 Gold Corp Files for OTCQB Uplisting, Provides Financial Update • ELEM • Jun 11, 2024 9:25 AM